
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Eloxatin shows +ve results in tumor inhibition

September 11, 2013 | News | By BioSpectrum Bureau



Singapore: Australia-based Starpharma Holdings has achieved improved tumor-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, Eloxatin (Oxaliplatin).

These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin when compared with Eloxatin in a colon cancer model (xenograft).

Oxaliplatin is sold as Eloxatin by Sanofi and achieved sales of approximately $2 billion in 2012. It is primarily used to treat colon and colorectal cancer. Bone marrow toxicities, including the serious white blood cell disorder, neutropenia, are reported in a high proportion of patients receiving Oxaliplatin, with rates in excess of 70 percent.

The observation that Starpharma's dendrimer-enhanced oxaliplatin nanoparticles substantially reduced neutropenia, a life threatening and dose-limiting toxicity, is an important finding both for this drug candidate and also for Starpharma's platform more broadly.

Ã?Â¢Ã¢â??Â¬Ã â??These are impressive results, that demonstrate Starpharma's dendrimer technology can be used to both enhance the efficacy and improve the safety profile of oxaliplatin, a widely used cancer treatment,Ã?Â¢Ã¢â??Â¬Ã?Â• said Starpharma CEO Dr Jackie Fairley. Dendrimer-enhanced oxaliplatin is being developed as part of Starpharma's internal drug delivery program.